Pere Barba

906 total citations
17 papers, 67 citations indexed

About

Pere Barba is a scholar working on Oncology, Immunology and Genetics. According to data from OpenAlex, Pere Barba has authored 17 papers receiving a total of 67 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Immunology and 4 papers in Genetics. Recurrent topics in Pere Barba's work include CAR-T cell therapy research (13 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Biosimilars and Bioanalytical Methods (4 papers). Pere Barba is often cited by papers focused on CAR-T cell therapy research (13 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Biosimilars and Bioanalytical Methods (4 papers). Pere Barba collaborates with scholars based in Spain, United States and Germany. Pere Barba's co-authors include Gloria Iacoboni, Kai Rejeski, Razan Mohty, Yucai Wang, Sabela Bobillo, Fabian Müller, Frederick L. Locke, Marion Subklewe, Juan C. Nieto and Wolfgang Bethge and has published in prestigious journals such as Blood, Bone Marrow Transplantation and European Journal Of Haematology.

In The Last Decade

Pere Barba

13 papers receiving 67 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pere Barba Spain 4 59 15 14 13 13 17 67
Jaap A. van Doesum Netherlands 6 46 0.8× 23 1.5× 6 0.4× 10 0.8× 7 0.5× 11 63
Alexander M. Leipold Germany 4 38 0.6× 15 1.0× 9 0.6× 14 1.1× 8 0.6× 7 63
Holly McConville United States 4 63 1.1× 17 1.1× 9 0.6× 11 0.8× 17 1.3× 5 76
Ariel Perez Perez United States 4 111 1.9× 19 1.3× 10 0.7× 19 1.5× 22 1.7× 11 118
Ben Uttenthal United Kingdom 3 73 1.2× 31 2.1× 10 0.7× 18 1.4× 13 1.0× 8 102
Diana Bouhassira United States 4 84 1.4× 17 1.1× 12 0.9× 30 2.3× 28 2.2× 7 125
Paulina Horvei United States 4 30 0.5× 13 0.9× 15 1.1× 14 1.1× 12 0.9× 9 57
Claudia Manriquez Roman United States 5 56 0.9× 13 0.9× 4 0.3× 20 1.5× 16 1.2× 15 62
Sabine Tischer‐Zimmermann Germany 5 79 1.3× 26 1.7× 5 0.4× 13 1.0× 21 1.6× 12 99
Marius Bartels Germany 3 48 0.8× 9 0.6× 37 2.6× 17 1.3× 16 1.2× 6 94

Countries citing papers authored by Pere Barba

Since Specialization
Citations

This map shows the geographic impact of Pere Barba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pere Barba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pere Barba more than expected).

Fields of papers citing papers by Pere Barba

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pere Barba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pere Barba. The network helps show where Pere Barba may publish in the future.

Co-authorship network of co-authors of Pere Barba

This figure shows the co-authorship network connecting the top 25 collaborators of Pere Barba. A scholar is included among the top collaborators of Pere Barba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pere Barba. Pere Barba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Bastos‐Oreiro, Mariana, Gloria Iacoboni, Vı́ctor Navarro, et al.. (2025). Chimeric antigen receptor T‐cell therapy outcomes in T cell/histiocyte‐rich large B‐cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study. HemaSphere. 9(2). e70077–e70077. 1 indexed citations
2.
3.
Díaz, Juan Manuel Mancilla, Saurabh Dahiya, Maeve O’Reilly, et al.. (2024). Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies. Blood. 144(Supplement 1). 7239–7239.
4.
Rejeski, Kai, Yucai Wang, Doris K. Hansen, et al.. (2024). Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality. Blood Advances. 8(8). 1857–1868. 29 indexed citations
5.
Rudilla, Francesc, Luís Larrea, Manuel Guerreiro, et al.. (2024). Development and characterization of a cell donor registry for virus‐specific T cell manufacture in a blood bank. HLA. 103(3). e15419–e15419. 3 indexed citations
6.
Sánchez‐Pina, José María, Lucía López‐Corral, Anabelle Chinea, et al.. (2024). Treatment with Siltuximab for Short Term Complications after Chimeric Antigen Receptor T-Cell Therapy: A Multicenter Retrospective Analysis. Blood. 144(Supplement 1). 7220–7220.
7.
Pernas, Berta, Gloria Iacoboni, Ibai Los‐Arcos, et al.. (2024). Patients with aggressive B‐cell lymphoma receiving CAR T‐cell therapy have a low rate of severe infections despite lack of universal antibacterial and antifungal prophylaxis. European Journal Of Haematology. 113(2). 227–234. 3 indexed citations
8.
9.
Rejeski, Kai, Doris K. Hansen, Yucai Wang, et al.. (2023). Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality. Blood. 142(Supplement 1). 359–359. 1 indexed citations
10.
Abramson, Jeremy S., Aravind Ramakrishnan, Ana Alfonso Piérola, et al.. (2023). Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL). Blood. 142(Supplement 1). 2110–2110. 11 indexed citations
11.
Barba, Pere, Junichiro Yuda, Maria Lia Palomba, et al.. (2023). A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell Malignancies. Blood. 142(Supplement 1). 3099–3099. 3 indexed citations
12.
Iacoboni, Gloria, Kai Rejeski, Annalisa Chiappella, et al.. (2021). Real-World Evidence of Brexucabtagene Autoleucel for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma. Blood. 138(Supplement 1). 2827–2827. 7 indexed citations
13.
Bobillo, Sabela, Juan C. Nieto, & Pere Barba. (2021). Use of checkpoint inhibitors in patients with lymphoid malignancies receiving allogeneic cell transplantation: a review. Bone Marrow Transplantation. 56(8). 1784–1793. 5 indexed citations
14.
Rejeski, Kai, Gloria Iacoboni, Olaf Penack, et al.. (2021). The CAR-Hematotox Identifies Patients at High Risk for Prolonged Neutropenia, Infectious Complications and Prolonged Hospitalization Following CD19-CART in R/R LBCL. Blood. 138(Supplement 1). 3852–3852. 1 indexed citations
15.
16.
Gallardo, David, Salut Brunet, Pau Montesinos, et al.. (2013). Therapy Related Acute Lymphoblastic Leukemia: Pethema Experience. Blood. 122(21). 4994–4994.
17.
Barba, Pere, Antònia Sampol, María Calbacho, et al.. (2011). Clofarabine-Based Chemotherapy for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. the Spanish Experience. Blood. 118(21). 4246–4246. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jaap A. van Doesum Breakdown of academic impact, for papers by Alexander M. Leipold Breakdown of academic impact, for papers by Holly McConville Breakdown of academic impact, for papers by Ariel Perez Perez Breakdown of academic impact, for papers by Ben Uttenthal Breakdown of academic impact, for papers by Diana Bouhassira Breakdown of academic impact, for papers by Paulina Horvei Breakdown of academic impact, for papers by Claudia Manriquez Roman Breakdown of academic impact, for papers by Sabine Tischer‐Zimmermann Breakdown of academic impact, for papers by Marius Bartels
Rankless by CCL
2026